In a human organoid-based mechanistic investigation, researchers revealed how an immunosuppressive drug, antithymocyte ...

An MUSC research team reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that contribute to fetal brain inflammation and ...

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...